Brookline analyst Kemp Dolliver downgraded NightHawk Biosciences to Hold from Buy and removed the firm’s price target, stating that it needs more clarity on the company’s pivot.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NHWK:
